Nanda-6e01e19b
Dr. Ranjan Kumar Nanda, Group Leader, ICGEB

Metabolic Phenotyping in Pulmonary Tuberculosis

Conference Talk by Dr. Nanda

Talk Abstract: Although medication for tuberculosis is available still it remains a major killer in India. The focus is to characterize the metabolic components in the biofluids of the drug naïve tuberculosis patients to understand disease manifestation and explain heterogeneity. Comparative metabolic phenotyping of biofluids of active fresh cases of tuberculosis and non-tuberculosis patients, using mass spectrometry based tools, might be useful to characterize the perturbed conditions. Employing clinical chemistry and chemometric analyses might be useful to get leads that may translate into developing a point of care diagnostic solution or appropriate therapeutic interventions.

In this talk, Dr. Nanda will discuss ongoing activities of his laboratory with particular emphasis to tuberculosis and how metabolomics could be used tools to better understand tuberculosis disease.

You can interact with Dr. Ranjan Kumar Nanda at Metabolomics India 2017 on 15 September at Hotel LeMeridian, Bengaluru, India.

Advertisements

The Determinants of Therapeutic Outcomes in Ayurveda: Challenges to Drug Discovery

Conference Talk by Dr. Raut

Dr. Ashwinikumar Raut
Dr. Ashwanikumar Raut, Director, KHMRC, Mumbai

Talk Abstract: Ayurveda is a clinically oriented healthcare system founded on nature-sensitive fundamental doctrines. Profundity of this clinical science is evident in its approach of considering every possible matter as a potential therapeutic substance. Integral therapeutic management in Ayurveda involves choice of diet, exercise, lifestyle, special procedures and drugs. The therapeutic outcome to the integral management is a conjoint response determined by the ‘Activity-Property Matrix’ of remedies used, effects of the non-drug measures and patient factors. Research in Ayurveda therapeutics demand a robust documentation of clinical observations, shared professional experiences, classical literature cue and Ayurvedic rationale to determine the productive outcome.

‘Observational Therapeutics’ and ‘Ayurvedic Pharmaco-epidemiology’ which attempt to address the experiences of clinical and community practices may provide hints and hits for the therapeutic choices in identified clinical conditions. However, making informed-intuitive choice from empirical-experiential noise is extremely crucial. A consensual validity of experts should guide the choices and outcome-determining variables of the drug response. This would guide further ‘Reverse pharmacology’ to rationally explore and translate these therapeutic experiences for novel clinical applications and new drug discovery, by appropriate and relevant experimental and clinical designs.

Dr. Raut proposes specific response determinants which would enhance the value of the R&D studies in Ayurveda and ensure translational outcomes as new drugs. These determinants can be broadly categorized into ‘product-specific’ and ‘patient-specific’ groups. Product-specific may be illustrated as Ayurvedic kalpa (classical form), Aushadhi prayoga (dosage regimen), Aushadhi kala (dosage regimen), Anupana (vehicle for administration), Ahara – Vihara (diet and life-style regimen) etc. Patient-specific factors are Rugna Prakriti (patient’s constitution), Shat–kriyakala (stage of a disease), Samutthana–Vishesha (causative factors), Dosh–Dushya–Adhishthan (pathological factors), Vyadhi Lakshana (clinical features) etc. Nevertheless, standardization and rationalization of traditional Ayurvedic products are also mandatory and integration of principles of Ayurvedic Pharmaceutics is equally essential for the healthcare of a large population.

Dr. Ashwinikumar Raut is Director, Clinical Research & Integrative Medicine at Kasturba Health Society’s Medical Research Centre, Mumbai. Dr. Raut is an Ayurveda consultant and Investigator from Mumbai.  He is faculty and consultant to premier medical institutes and hospitals in Mumbai. He also gives consultation to Ayurveda industry.

Gain more insights from Dr. Ashwinikumar Raut at SELECTBIO’s 5th International Drug Discovery Conference Drug Discovery India 2017 on 14-15 September 2017 at Hotel Le Meridien, Bengaluru.

How to develop Smaller and Cheaper Cell-Based Assays for HCA?

Assay Miniaturization Strategies:  Smaller and Cheaper Cell-Based Assays for HCA

Learn from Dr Anthony Davies, Director, TCIQ, Queensland, Australia at CellTech India 2015 in Bangalore on March 2-3, 2015.

Abstract

To sustain the viability of large-scale research programs running in academia and industry (especially when considering the current global economic climate), it is essential to reduce research costs wherever possible.  With the advent of micron resolution robotics and nano-litre capable liquid handlers, assay miniaturization for large-scale High-Content Screening is now possible. The advantages of miniaturization are clear, when one considers the savings in reagents and experimental materials and experimental turnaround times.  However miniaturization can also be costly to set up and difficult to deploy.

Cell Tech India 2015-2 698x400